Dr. Michael G. Abraham, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Kansas City, School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 129
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Missouri, Kansas City, School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
KS license 94-06683
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- University of Kansas Health System Olathe Hospital Olathe, KS
Medical groups
- Kansas University Physicians Inc (1,849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 129
- Services billed
- 338
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 54 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 40 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 23 | 21 |
| Insertion of tube into internal neck artery for diagnosis or treatment with review by radiologist | 22 | 21 |
| Insertion of tube into brain artery for diagnosis or treatment with review by radiologist | 19 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 15 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 13 |
| Ultrasonic guidance for blood vessel access | 13 | 11 |
| Insertion of tube into external neck artery for diagnosis or treatment with review by radiologist | 12 | 11 |
| Removal of blood clot and injection to dissolve blood clot from head artery using fluoroscopic guidance | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 11 payments worth $5,933 in total to this clinician.
| Imperative Care, Inc | $3,596 |
|---|---|
| Rapid Medical LTD | $1,750 |
| Qapel Medical Inc | $270 |
| DePuy Synthes Sales Inc. | $219 |
| Trisalus Life Sciences, Inc. | $46.93 |
| Inspiremd LTD | $32.68 |
| Cardiva Medical, Inc. | $17.95 |
| Consulting Fee | $5,250 |
|---|---|
| Food and Beverage | $683 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Imperative Care, Inc Sep 10, 2025 | Consulting Fee ZOOM 88-T LARGE DISTAL PLATFORM · VASCULAR | $3,500 |
| Rapid Medical LTD Apr 16, 2025 | Consulting Fee TIGERTRIEVER 17 REVASCULARIZATION DEVICE; COMANECI 17 · Neurovascular | $1,750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $29,832 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
Route 92 Medical, Inc. · Completed · NCT05018650
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.